January 24, 2019 / 6:07 AM / 5 months ago

BRIEF-Vifor Pharma and Chemocentryx Withdraw Marketing Authorisation Application For Avacopan

Jan 24 (Reuters) - Vifor Pharma AG:

* CHEMOCENTRYX ANNOUNCES WITHDRAWAL OF PHASE II-BASED CONDITIONAL MARKETING AUTHORISATION (CMA) APPLICATION FOR ANCA-ASSOCIATED VASCULITIS IN EUROPE, PHASE III ADVOCATE TRIAL DATA RELEASE PLANNED FOR Q4 2019

* PLAN TO FILE FOR FULL MARKETING APPROVAL TO EMA AND FDA IN 2020 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below